why haven't they targetted profitability?, page-7

Ventracor will survive 2009. i do not doubt the reliability any other claims by the company regarding the device. the issue i have always had with it is that there is a better device just as reliable and easier to implant and explant than Ventracors'. heartware continues to whether the stockmarket storm suprisingly well and is backed to the hilt by some of its directors. i believe as these devices get smaller and easier to implant the market will grow.
Heartware will dominate the market in 3-4 years time as long as no reliability issue becomes apparent in phase 3 trials. So far all reports are very promising. As for all other competitors in this field either come up with a device that is better or fade into the background. The Heartware product has clear advantages over all competitors and will dominate once approval is given.
Dont waste any more of your hard earned on Ventracor if it was that good sales in Europe should have been alot better.
there is nothing to suggest that the US market is going to be any different.
if anyone disagrees please explain?